glp 1 nutrition GLP-1 Support Stack: Save up to 20% Today with Our Bundle GLP-1 Diet Plan: What To

What are the major driving factors in the glucagon-like peptide 1 (GLP-1) agonist market

News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s

Participants who had been taking high dose Wegovy and switched to daily oral Foundayo regained an average of 0.9 kilograms (kg), or about 2 pounds (lbs) over 1 year

Studies and real-world use suggest that the injectable formulation can offer a more predictable and manageable side effect profile for most patients

NASH is also known to be associated with not only a high incidence of liver-related complications but also an increased risk of cardiovascular-related mortality and vascular complications [5]